1	The	_	_	DT	_	_	_	_	_
2	number	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	males	_	_	NNS	_	_	_	_	_
5	diagnosed	_	_	VBN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	prostate	_	_	NN	_	_	_	_	_
8	cancer	_	_	NN	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	PCa	_	_	NN	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	increasing	_	_	VBG	_	_	_	_	_
14	all	_	_	RB	_	_	_	_	_
15	over	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	world	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Most	_	_	JJS	_	_	_	_	_
2	patients	_	_	NNS	_	_	_	_	_
3	with	_	_	IN	_	_	_	_	_
4	early-stage	_	_	JJ	_	_	_	_	_
5	PCa	_	_	NN	_	_	_	_	_
6	can	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	treated	_	_	VBN	_	_	_	_	_
9	by	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	appropriate	_	_	JJ	_	_	_	_	_
12	therapy	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	such	_	_	JJ	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	radical	_	_	JJ	_	_	_	_	_
17	prostatectomy	_	_	NN	_	_	_	_	_
18	or	_	_	CC	_	_	_	_	_
19	irradiation	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	On	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	other	_	_	JJ	_	_	_	_	_
4	hand	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	androgen	_	_	NN	_	_	_	_	_
7	deprivation	_	_	NN	_	_	_	_	_
8	therapy	_	_	NN	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	ADT	_	_	NN	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	standard	_	_	JJ	_	_	_	_	_
15	systemic	_	_	JJ	_	_	_	_	_
16	therapy	_	_	NN	_	_	_	_	_
17	given	_	_	VBN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	patients	_	_	NNS	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	advanced	_	_	JJ	_	_	_	_	_
22	PCa	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	ADT	_	_	NNP	_	_	_	_	_
2	induces	_	_	VBZ	_	_	_	_	_
3	temporary	_	_	JJ	_	_	_	_	_
4	remission	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	but	_	_	CC	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	majority	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	patients	_	_	NNS	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	approximately	_	_	RB	_	_	_	_	_
13	60	_	_	CD	_	_	_	_	_
14	%	_	_	NN	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	eventually	_	_	RB	_	_	_	_	_
17	progress	_	_	VBP	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	castration-resistant	_	_	JJ	_	_	_	_	_
20	prostate	_	_	NN	_	_	_	_	_
21	cancer	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	CRPC	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	which	_	_	WDT	_	_	_	_	_
27	is	_	_	VBZ	_	_	_	_	_
28	associated	_	_	VBN	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	a	_	_	DT	_	_	_	_	_
31	high	_	_	JJ	_	_	_	_	_
32	mortality	_	_	NN	_	_	_	_	_
33	rate	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Generally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	well-differentiated	_	_	JJ	_	_	_	_	_
4	PCa	_	_	NN	_	_	_	_	_
5	cells	_	_	NNS	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	androgen-dependent	_	_	JJ	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	i.	_	_	FW	_	_	_	_	_
10	e.	_	_	FW	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	androgen	_	_	NN	_	_	_	_	_
13	receptor	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	AR	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	signaling	_	_	NN	_	_	_	_	_
18	regulates	_	_	VBZ	_	_	_	_	_
19	cell	_	_	NN	_	_	_	_	_
20	cycle	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	differentiation	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Loss	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	AR	_	_	NN	_	_	_	_	_
4	signaling	_	_	VBG	_	_	_	_	_
5	after	_	_	IN	_	_	_	_	_
6	ADT	_	_	NNP	_	_	_	_	_
7	triggers	_	_	VBZ	_	_	_	_	_
8	androgen-independent	_	_	JJ	_	_	_	_	_
9	outgrowth	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	generating	_	_	VBG	_	_	_	_	_
12	poorly	_	_	RB	_	_	_	_	_
13	differentiated	_	_	VBN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	uncontrollable	_	_	JJ	_	_	_	_	_
16	PCa	_	_	NN	_	_	_	_	_
17	cells	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Once	_	_	IN	_	_	_	_	_
2	PCa	_	_	NNP	_	_	_	_	_
3	cells	_	_	NNS	_	_	_	_	_
4	lose	_	_	VBP	_	_	_	_	_
5	their	_	_	PRP$	_	_	_	_	_
6	sensitivity	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	ADT	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	effective	_	_	JJ	_	_	_	_	_
11	therapies	_	_	NNS	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	limited	_	_	VBN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	last	_	_	JJ	_	_	_	_	_
4	few	_	_	JJ	_	_	_	_	_
5	years	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	however	_	_	RB	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	several	_	_	JJ	_	_	_	_	_
10	new	_	_	JJ	_	_	_	_	_
11	options	_	_	NNS	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	treatment	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	CRPC	_	_	NNP	_	_	_	_	_
17	have	_	_	VBP	_	_	_	_	_
18	been	_	_	VBN	_	_	_	_	_
19	approved	_	_	VBN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	e.	_	_	FW	_	_	_	_	_
22	g.	_	_	NNP	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	CYP17	_	_	NNP	_	_	_	_	_
26	inhibitor	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	AR	_	_	NN	_	_	_	_	_
30	antagonist	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	taxane	_	_	NN	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Despite	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	progress	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	development	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	new	_	_	JJ	_	_	_	_	_
9	drugs	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	there	_	_	EX	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	high	_	_	JJ	_	_	_	_	_
15	medical	_	_	JJ	_	_	_	_	_
16	need	_	_	NN	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	optimizing	_	_	VBG	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	sequence	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	combination	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	approved	_	_	VBN	_	_	_	_	_
25	drugs	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	identification	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	predictive	_	_	JJ	_	_	_	_	_
6	biomarkers	_	_	NNS	_	_	_	_	_
7	may	_	_	MD	_	_	_	_	_
8	help	_	_	VB	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	context	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	personalized	_	_	VBN	_	_	_	_	_
14	medicine	_	_	NN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	guide	_	_	VB	_	_	_	_	_
17	treatment	_	_	NN	_	_	_	_	_
18	decisions	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	improve	_	_	VB	_	_	_	_	_
21	clinical	_	_	JJ	_	_	_	_	_
22	outcomes	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	prevent	_	_	VB	_	_	_	_	_
26	unnecessary	_	_	JJ	_	_	_	_	_
27	side	_	_	NN	_	_	_	_	_
28	effects	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	Departments	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	Nephro-Urologic	_	_	NNP	_	_	_	_	_
4	Surgery	_	_	NNP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	Andrology	_	_	NNP	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	Professor	_	_	NNP	_	_	_	_	_
9	Emeritus	_	_	NNP	_	_	_	_	_
10	Yoshiki	_	_	NNP	_	_	_	_	_
11	Sugimura	_	_	NNP	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	Oncologic	_	_	NNP	_	_	_	_	_
15	Pathology	_	_	NNP	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	Professor	_	_	NNP	_	_	_	_	_
18	Emeritus	_	_	NNP	_	_	_	_	_
19	Taizo	_	_	NNP	_	_	_	_	_
20	Shiraishi	_	_	NNP	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	Mie	_	_	NNP	_	_	_	_	_
24	University	_	_	NNP	_	_	_	_	_
25	Graduate	_	_	NNP	_	_	_	_	_
26	School	_	_	NNP	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	Medicine	_	_	NNP	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	organized	_	_	VBD	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	semi-closed	_	_	VBN	_	_	_	_	_
33	symposium	_	_	NN	_	_	_	_	_
34	on	_	_	IN	_	_	_	_	_
35	Biology	_	_	NNP	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	Prostate	_	_	NNP	_	_	_	_	_
38	Gland	_	_	NNP	_	_	_	_	_
39	Ise-Shima	_	_	NNP	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	symposium	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	started	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	2002	_	_	CD	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	held	_	_	VBN	_	_	_	_	_
10	every	_	_	DT	_	_	_	_	_
11	four	_	_	CD	_	_	_	_	_
12	years	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	2006	_	_	CD	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	2010	_	_	CD	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	2014	_	_	CD	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	2018	_	_	CD	_	_	_	_	_
22	without	_	_	IN	_	_	_	_	_
23	any	_	_	DT	_	_	_	_	_
24	financial	_	_	JJ	_	_	_	_	_
25	support	_	_	NN	_	_	_	_	_
26	from	_	_	IN	_	_	_	_	_
27	pharmaceutical	_	_	JJ	_	_	_	_	_
28	companies	_	_	NNS	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	chemical	_	_	JJ	_	_	_	_	_
31	industries	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Each	_	_	DT	_	_	_	_	_
2	year	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	symposium	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	attended	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	40	_	_	CD	_	_	_	_	_
10	â€“	_	_	:	_	_	_	_	_
11	50	_	_	CD	_	_	_	_	_
12	Japanese	_	_	JJ	_	_	_	_	_
13	investigators	_	_	NNS	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	expertise	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	interest	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	biology	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	prostate	_	_	NN	_	_	_	_	_
23	gland	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	PCa	_	_	NNP	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	goal	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	symposium	_	_	NN	_	_	_	_	_
6	was	_	_	VBD	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	discuss	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	biological	_	_	JJ	_	_	_	_	_
11	mechanism	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	development	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	progression	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	prostatic	_	_	JJ	_	_	_	_	_
19	proliferative	_	_	JJ	_	_	_	_	_
20	diseases	_	_	NNS	_	_	_	_	_
21	such	_	_	JJ	_	_	_	_	_
22	as	_	_	IN	_	_	_	_	_
23	benign	_	_	JJ	_	_	_	_	_
24	prostatic	_	_	JJ	_	_	_	_	_
25	hyperplasia	_	_	NN	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	BPH	_	_	NN	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	PCa	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	major	_	_	JJ	_	_	_	_	_
3	topic	_	_	NN	_	_	_	_	_
4	areas	_	_	NNS	_	_	_	_	_
5	were	_	_	VBD	_	_	_	_	_
6	discussed	_	_	VBN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	e.	_	_	FW	_	_	_	_	_
9	g.	_	_	FW	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	pathophysiology	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	BPH	_	_	NNP	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	tumor	_	_	NN	_	_	_	_	_
18	microenvironment	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	PCa	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	AR	_	_	NN	_	_	_	_	_
23	signaling	_	_	VBG	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	PCa	_	_	NNP	_	_	_	_	_
26	progression	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	development	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	PCa	_	_	NN	_	_	_	_	_
33	detection	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	diagnosis	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	Special	_	_	NNP	_	_	_	_	_
3	Issue	_	_	NN	_	_	_	_	_
4	includes	_	_	VBZ	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	major	_	_	JJ	_	_	_	_	_
7	topics	_	_	NNS	_	_	_	_	_
8	discussed	_	_	VBN	_	_	_	_	_
9	at	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	symposium	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	2018	_	_	CD	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	Special	_	_	NNP	_	_	_	_	_
4	Issue	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	focused	_	_	VBD	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	cytobiology	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	human	_	_	JJ	_	_	_	_	_
12	PCa	_	_	NN	_	_	_	_	_
13	cells	_	_	NNS	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	its	_	_	PRP$	_	_	_	_	_
16	clinical	_	_	JJ	_	_	_	_	_
17	applications	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	develop	_	_	VB	_	_	_	_	_
20	a	_	_	DT	_	_	_	_	_
21	major	_	_	JJ	_	_	_	_	_
22	step	_	_	NN	_	_	_	_	_
23	towards	_	_	IN	_	_	_	_	_
24	personalized	_	_	VBN	_	_	_	_	_
25	medicine	_	_	NN	_	_	_	_	_
26	matched	_	_	VBN	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	individual	_	_	JJ	_	_	_	_	_
30	needs	_	_	NNS	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	patients	_	_	NNS	_	_	_	_	_
33	with	_	_	IN	_	_	_	_	_
34	early-stage	_	_	JJ	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	advanced	_	_	JJ	_	_	_	_	_
37	PCa	_	_	NN	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	CRPC	_	_	NNP	_	_	_	_	_
40	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	hope	_	_	VBP	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	Special	_	_	NNP	_	_	_	_	_
6	Issue	_	_	NN	_	_	_	_	_
7	attracts	_	_	VBZ	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	lot	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	attention	_	_	NN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	readers	_	_	NNS	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	expertise	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	interest	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	cytobiology	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	human	_	_	JJ	_	_	_	_	_
23	PCa	_	_	NN	_	_	_	_	_
24	cells	_	_	NNS	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	its	_	_	PRP$	_	_	_	_	_
27	clinical	_	_	JJ	_	_	_	_	_
28	applications	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_

